Treatment approach to newly diagnosed diffuse large B-cell lymphoma.

Abstract:

:Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of non-Hodgkin lymphoma in western countries. High prognostic heterogeneity is observed among patients with DLBCL with long-term survival ranging from 30% to more than 90% according to clinic-biological prognostics such as the International Prognostic Index (IPI) and its subsequent revised variants. Recent advances in the understanding of DLBCL biology as cell-of-origin (COO) determination has led to significant improvement of prognostic tools but also shed light on new potential targeted compounds for specific DLBCL subtypes. First DLBCL subset has been designed germinal center B-cell like DLBCL (GCB) because it expresses genes characteristic of germinal center B cells. Second DLBCL subset has been designed activated B-cell like DLBCL (ABC) because it expresses genes upregulated in response to in vitro activation. In this review, we will present state-of-the-art treatment of DLBCL in young and elderly patients, recent results in dose-dense regimen as well as potential interest for high-dose therapy followed by autologous stem cell transplant. A special emphasis will be given to new treatment developments according to COO in DLBCL. In particular, we will focus on new drugs that might alleviate the worse prognosis associated to DLBCL ABC subtype in the near future.

journal_name

Semin Hematol

journal_title

Seminars in hematology

authors

Bachy E,Salles G

doi

10.1053/j.seminhematol.2015.01.001

subject

Has Abstract

pub_date

2015-04-01 00:00:00

pages

107-18

issue

2

eissn

0037-1963

issn

1532-8686

pii

S0037-1963(15)00002-5

journal_volume

52

pub_type

杂志文章,评审
  • Copper deficiency in humans.

    abstract::Copper is an essential trace element that is required for a number of enzymes which are necessary for normal metabolic function. Metabolic balance studies have demonstrated that daily copper losses are approximately 1.3 mg/day. In order to remain in copper balance, the average adult male must consume a diet which cont...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Williams DM

    更新日期:1983-04-01 00:00:00

  • Effects of granulocyte-macrophage colony-stimulating factor in iatrogenic myelosuppression, bone marrow failure, and regulation of host defense.

    abstract::In early studies, recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) has been found to reduce the depth and duration of granulocytopenia in the settings of cancer chemotherapy and autologous bone marrow transplantation. In patients with myelodysplastic syndrome or aplastic anemia. GM-CSF has p...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Gutterman J,Vadhan-Raj S,Logothetis C,Anaissle E,Estey E,Talpaz M,Kurzrock R

    更新日期:1990-07-01 00:00:00

  • Familial thrombophilia: a complex genetic disorder.

    abstract::Familial thrombosis has long been considered as an autosomal dominant trait, caused by a dominant gene defect with a reduced penetrance for the disease. Recently, this view has changed and today familial thrombophilia is considered as a complex genetic disorder caused by the segregation of two or more gene defects (kn...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Koeleman BP,Reitsma PH,Bertina RM

    更新日期:1997-07-01 00:00:00

  • The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma.

    abstract::The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, procarbazine (COP-BLAM) programs of combination chemotherapy were administered to patients with advanced diffuse large cell lymphoma. The original COP-BLAM programs were designed to deliver intense multidrug therapy maximizing tumor kill. COP-BLAM ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:

    authors: Coleman M,Armitage JO,Gaynor M,McDermott D,Weisenburger DD,Adler K,Beshevkin M,Silver RT,Reisman AM,Pasmantier MW

    更新日期:1988-04-01 00:00:00

  • Future strategies toward the cure of indolent B-cell malignancies. Immune recognition and antiself.

    abstract::Tumor cells from patients with B-cell malignancies exhibit a number of immunophenotypic characteristics that may be responsible for their survival. It has been shown, for example, that down-modulation of CD154 (CD40 ligand), which allows B cells to respond to T cells, may account for some of the immune defects of thes...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Nadler LM

    更新日期:1999-10-01 00:00:00

  • Towards molecular diagnosis and targeted therapy of lymphoid malignancies.

    abstract::Gene expression profiling of cancer began as a research tool but is rapidly moving towards clinical application. The diagnostic category of diffuse large B-cell lymphoma (DLBCL) can now be viewed as an amalgam of several different diseases that have distinct gene expression profiles, oncogenic mechanisms, and clinical...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(03)00194-x

    authors: Wiestner A,Staudt LM

    更新日期:2003-10-01 00:00:00

  • Idiopathic thrombocytopenia purpura: Treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D therapy.

    abstract::A retrospective study was conducted to determine treatment patterns for idiopathic thrombocytopenia purpura (ITP) across the US and to determine the cost of its treatment with high-dose intravenous immunoglobulin (IVIg) and anti-D therapy. Information on the incidence, treatment patterns, hospital care, and costs for ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:

    authors: Simpson KN,Coughlin CM,Eron J,Bussel JB

    更新日期:1998-01-01 00:00:00

  • The potential role of new therapies in deep-vein thrombosis prophylaxis.

    abstract::The value of prophylaxis against venous thromboembolism (VTE) is increasingly accepted in most surgical specialties, although the potential reduction in fatal pulmonary embolism has recently been questioned. The burden of VTE in hospital patients nevertheless remains high, partly attributable to underuse of thrombopro...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2001.25188

    authors: Wille-Jørgensen P

    更新日期:2001-04-01 00:00:00

  • Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia.

    abstract::Comprehensive study of the major chromosomal/molecular abnormalities in children and adults with acute lymphoblastic leukemia (ALL) has demonstrated prognostic utility for many of these anomalies, to the extent that cytogenetic and molecular genetic evaluations are now required for optimal clinical management of newly...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(00)90018-0

    authors: Ferrando AA,Look AT

    更新日期:2000-10-01 00:00:00

  • Treatment of hemangiomatosis with recombinant interferon alfa.

    abstract::Hemangiomas and lymphangiomas are two main types of angiomatous disease that occur most commonly in infancy and childhood. Most hemangiomas resolve spontaneously, but some endanger vital structures such as the lung, as in pulmonary hemangiomatosis, a rare and universally fatal disease. Occasionally, hemangiomatous les...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: White CW

    更新日期:1990-07-01 00:00:00

  • Resistance to imatinib: mutations and beyond.

    abstract::Mechanisms of resistance to the tyrosine kinase inhibitor (TKI) imatinib had been modeled in vitro even prior to the first reports of clinical resistance in patients with chronic myeloid leukemia (CML). The discovery that BCR-ABL is reactivated at the time of resistance and the unveiling of point mutations within the ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2010.06.005

    authors: La Rosée P,Deininger MW

    更新日期:2010-10-01 00:00:00

  • Transplant decision-making strategies in the myeloproliferative disorders.

    abstract::Myelofibrosis with myeloid metaplasia, also known as idiopathic myelofibrosis (IF) or agnogenic myeloid metaplasia, is one of the characteristic manifestations of polycythemia vera (PV) in the spent phase, and has a particularly adverse prognosis. IF may also present de novo. To date, treatment strategies for both spe...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2003.50032

    authors: Fruchtman SM

    更新日期:2003-01-01 00:00:00

  • Fc receptor blockade and immune thrombocytopenic purpura.

    abstract::Inhibition of antibody-coated platelet destruction in patients with immune thrombocytopenic purpura (ITP) is a well-known mechanism of treatment effect. A number of interventions that would ameliorate the thrombocytopenic effect of ITP patient plasma when infused into normal recipients were demonstrated in 1965. Subse...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(00)90104-5

    authors: Bussel JB

    更新日期:2000-07-01 00:00:00

  • Who is the best donor for haploidentical stem cell transplantation?

    abstract::Recent advances in haploidentical stem cell transplantation have enabled the use of human leukocyte antigen-half matched related donors for allogeneic stem cell transplantation and helped overcome one of the most important limitation in transplantation, which is donor availability, especially for the non-Caucasian pop...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2018.08.003

    authors: Kongtim P,Ciurea SO

    更新日期:2019-07-01 00:00:00

  • Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia.

    abstract::Bone marrow transplantation (BMT) from a human leukocyte antigen (HLA)-matched sibling is the treatment of choice in children and young adults with severe aplastic anemia (SAA). However, because only 30% of patients have a suitable donor, more aggressive nontransplant immunosuppressive regimens have been used, with re...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(00)90029-5

    authors: Margolis DA,Casper JT

    更新日期:2000-01-01 00:00:00

  • Quality of life, social challenges, and psychosocial support for long-term survivors after allogeneic hematopoietic stem-cell transplantation.

    abstract::Over the last two decades quality of life (QoL) and the social challenges of allogeneic hematopoietic stem cell transplant (allo-HSCT) survivors have been emerging as subjects of extensive research and are now considered as very important aspects in the pretransplant evaluation and management of allo-HSCT recipients. ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2011.10.004

    authors: Norkin M,Hsu JW,Wingard JR

    更新日期:2012-01-01 00:00:00

  • Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.

    abstract::Hodgkin Lymphoma (HL) is a lymphoproliferative disorder of B cells that commonly has a favorable prognosis when treated with either combination chemotherapy and radiation therapy, or chemotherapy alone. However, the prognosis for patients who relapse, or have evidence for refractory disease, is poor and new treatments...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2016.05.011

    authors: Younes A,Ansell SM

    更新日期:2016-07-01 00:00:00

  • The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS.

    abstract::The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry enrolls all consecutive patients for whom plasma exchange treatment is requested for clinically diagnosed TTP-HUS within a defined geographic region. During 14.5 years, from January 1, 1989 until June 30, 2003, 301 patients h...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:10.1053/j.seminhematol.2003.10.001

    authors: George JN,Vesely SK,Terrell DR

    更新日期:2004-01-01 00:00:00

  • Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.

    abstract::The immunomodulatory drug (IMiD) lenalidomide is a more potent immunomodulator than thalidomide with respect to its effects on cytokine modulation and increased T-cell proliferation. Of all the IMiDs, clinical trial data are most mature for lenalidomide. In phase I studies, dose-limiting toxicities of lenalidomide wer...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2005.10.004

    authors: Richardson P

    更新日期:2005-10-01 00:00:00

  • Prognostic relevance of clinical risk factors in mantle cell lymphoma.

    abstract::Mantle cell lymphoma (MCL) has only recently been recognized as a separate biologically defined lymphoma entity. Due to its low incidence, many reports on clinical prognostic factors are limited by small patient numbers. The MCL International Prognostic Index (MIPI) was developed using data of more than 400 patients t...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2011.06.001

    authors: Hoster E

    更新日期:2011-07-01 00:00:00

  • Surface and cytoskeletal events regulating leukocyte membrane topography.

    abstract::The experiments reviewed here establish that surface components and surface functions can assume predictable, asymmetric patterns within the continuous plasma membranes of mammalian leukocytes. Recent biophysical and morphological studies show that receptor redistribution can occur very rapidly and that a unique geome...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Oliver JM,Berlin RD

    更新日期:1983-10-01 00:00:00

  • Advances in the treatment of von Willebrand disease.

    abstract::Von Willebrand disease (VWD) is the most commonly inherited bleeding disorder, caused by inheritance of a quantitative or qualitative abnormality of von Willebrand factor (VWF). While the majority of patients with VWD are successfully treated with adjunctive therapies or with the synthetic vasopressin analog desmopres...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(01)90131-3

    authors: Hambleton J

    更新日期:2001-10-01 00:00:00

  • Transplant outcomes in bone marrow failure syndromes and hemoglobinopathies.

    abstract::Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potential cure for most bone marrow (BM) failure syndromes and hemoglobinopathies. Over the past decade, umbilical cord blood (UCB) has been used more frequently as a stem cell source in patients who lack a suitable BM donor. Although graft failure ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2009.10.004

    authors: MacMillan ML,Walters MC,Gluckman E

    更新日期:2010-01-01 00:00:00

  • Surgery in hemophilia. The general view: patient selection, timing, and preoperative assessment.

    abstract::Although often overlooked, the life of the patient with severe hemophilia is characterized by both intermittent and chronic pain. Bleeds into joints and muscles cause extensive pressure on sensory nerves and, following recurrent bleeds, joint destruction, and synovial reaction is accompanied by constant pains that are...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2005.11.024

    authors: Ingerslev J,Hvid I

    更新日期:2006-01-01 00:00:00

  • Recombinant factor VIIa (Novoseven) as a hemostatic agent.

    abstract::Recombinant activated factor VII (rFVIIa; NovoSeven, Novo Nordisk, Denmark) induces hemostasis in life- and limb-threatening bleeds and in major surgery of hemophilia A and B patients, regardless of inhibitor titer. A total of more than 6,500 patients have been treated, and NovoSeven has been administered in more than...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(01)90147-7

    authors: Hedner U

    更新日期:2001-10-01 00:00:00

  • Activity survey and historical perspective of autologous stem cell transplantation in Europe.

    abstract::Autologous hematopoietic stem cell transplantation (HSCT) has a long tradition in Europe. Initially developed as a tool to restore rapid remission or chronic phase in patients with advanced leukemia without a sibling donor, it evolved over the last three decades to be used as a standard tool in patients with malignanc...

    journal_title:Seminars in hematology

    pub_type: 历史文章,杂志文章

    doi:10.1053/j.seminhematol.2007.09.001

    authors: Gratwohl A

    更新日期:2007-10-01 00:00:00

  • Diagnosis and epidemiology of human herpesvirus 8 infection.

    abstract::There is consensus that human herpesvirus 8 (HHV-8) is a necessary, albeit not sufficient, causal agent of Kaposi's sarcoma (KS). In the past several years, there have been rapid advances in our understanding of HHV-8 infection. In diagnosis, antibody detection is more sensitive than nucleic acid-based techniques. Whi...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2003.50013

    authors: Martin JN

    更新日期:2003-04-01 00:00:00

  • New anti-thrombotic agents: emphasis on hemorrhagic complications and their management.

    abstract::Our advanced knowledge of coagulation has led to the synthesis of novel procoagulant substances, such as recombinant activated factor VII (rFVIIa; NovoSeven, Novo Nordisk, Bagsvaerd, Denmark). Similarly, in-depth understanding of the interaction between anticoagulant proteins and their natural inhibitors has led to th...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2005.11.023

    authors: Ng HJ,Crowther MA

    更新日期:2006-01-01 00:00:00

  • Rituximab in indolent lymphomas.

    abstract::Indolent non-Hodgkin lymphoma (NHL) comprises a group of incurable, generally slow-growing lymphomas highly responsive to initial therapy, with a relapsing and progressive course. Rituximab, an anti-CD20 antibody, has had a large impact on the treatment of indolent NHL. Its effectiveness as a single agent and in conju...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2010.01.003

    authors: Sousou T,Friedberg J

    更新日期:2010-04-01 00:00:00

  • Neonatal thrombocytopenia and megakaryocytopoiesis.

    abstract::Thrombocytopenia is common among sick neonates, affecting 20% to 35% of all patients admitted to the neonatal intensive care unit (NICU). While most cases of neonatal thrombocytopenia are mild or moderate and resolve within 7 to 14 days with appropriate therapy, 2.5% to 5% of NICU patients develop severe thrombocytope...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2010.04.002

    authors: Ferrer-Marin F,Liu ZJ,Gutti R,Sola-Visner M

    更新日期:2010-07-01 00:00:00